drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
An autologous CD19-directed CAR T-cell therapy (also known as CNCT19) in which a patient’s T cells are genetically modified to express a chimeric antigen receptor targeting CD19 on B-lineage cells to eliminate residual leukemic cells.
nci_thesaurus_concept_id
C199061
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically modified to express a CD19‑specific chimeric antigen receptor. Binding to CD19 on B‑lineage cells triggers T‑cell activation, expansion, cytokine release, and perforin/granzyme‑mediated cytotoxicity, eliminating CD19‑positive leukemic (and normal) B cells to clear residual disease.
drug_name
Inaticabtagene autoleucel
nct_id_drug_ref
NCT06608732